A potent tubulin inhibitor that is a toxin payload in antibody drug conjugates (ADCs)..

A potent TNFα/TNFRc1 interaction antagonist with IC50 of 50 nM, with no affinity for the related cytokine receptors TNFRc2 or CD40, and no cytotoxicity (>100 uM).

A potent TLR7 agonist with EC50 of 8.6 nM. .

A potent TLR7 agonist with EC50 of 59 nM..

A potent STAT5 inhibitor with a dual mechanism of action, potently inhibits STAT5 through liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition at 200-300 nM.

A potent Src inhibitor extracted from patent WO/2012003544A1..

A potent SR-3 antagonist

A potent small-molecule inhibitor of the MIR155 host gene/miR-155 axis.

A potent small molecule inhibitor that binds and disrupts the MDM2/MDMX-p53 interaction with IC50 of 0.19 uM and 19.7 uM, respectively..

A potent small molecule inhibitor of MELK kinase activity with IC50 of 42 nM.

A potent RIG-I-like receptor (RLR) agonist that triggers IRF3-dependent innate immune antiviral genes and IFN-β expression.

A potent respiratory syncytial virus (RSV) fusion inhibitor..

A potent psychopharmacologic agent that shows high affinity for 5-HT, dopamine, histamine and adrenoceptors.

A potent protein tyrosine kinase inhibitor that shows selectivity for PDGFR in vitro and in cells.

A potent photoaffinity ligand for the peripheral-type benzodiazepine binding site with Ki of 4 nM.

A potent phosphodiesterase 12 (PDE12) with Ki of 17.5 nM, with no activity for related enzyme CNOT6 (Ki>10 uM).

A potent PfDHODH inhibitor that exhibits low nanomolar in vitro potency against DHODH from P falciparum, P vivax, and P berghei.

A potent PDE4 inhibitor with IC50 of 94.5 nM..

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 80 nM in a homogenous time-resolved fluorescence binding assay..

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 6-100 nM in a homogenous time-resolved fluorescence binding assay..

A potent pan-HDAC inhibitor with IC50 of 16-30 nM, inhibits cell proliferation of P815, C2, and BR cells with IC50 of 0.65, 0.30, and 0.23 uM, respectively.

A potent nucleoside analog reverse transcriptase inhibitor (nRTI). An analog of cytidine that can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. Needs to be phosphorylated to its triphosphate

A potent non-peptide antagonist of tachykinin NK2 receptor with pKi of 9.5 in CHO cells.

A potent non-nucleoside RSV L-protein polymerase inhibitor with IC50 of 89 nM.

A potent non-nucleoside RSV L-protein polymerase inhibitor with EC50 of 0.01 uM and 1.3 uM for RSV A2 and RSV B-WST, respectively.

A potent neutral endopeptidase EC 3.4.24.11 (atriopeptidase) inhibitor that increases endogenous ANF levels and produces natriuretic and diuretic responses intravenously in mice..

A potent mutant Src T338C inhibitor with IC50 of 111 nM.

A potent monoamine oxidase B (MAO-B) inhibitor..

A potent microtubule inhibitor that not only inhibits the expression levels of HIF-1α protein but also destabilizes HIF-1α mRNA.

A potent MDM2-p53 interaction inhibitor with remarkable biochemical (HTRF IC50=0.4 nM), cellular potency (SJSA-1 EdU IC50=25 nM), and favorable pharmacokinetic properties.